001970 |
Bernard Zinman [Canada] ; Greg Fulcher [Australie] ; Paturi V. Rao [Inde] ; Nihal Thomas [Inde] ; Lars A. Endahl [Danemark] ; Thue Johansen [États-Unis] ; Rebecka Lindh [États-Unis] ; Andrew Lewin [États-Unis] ; Julio Rosenstock [États-Unis] ; Michel Pinget [France] ; Chantal Mathieu [Belgique] | Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial |